|
1
|
Yang SS, Brough AJ and Bernstein J: Tumors
of the liver in early infancy: Hepatoblastoma. Mich Med.
71:539–543. 1972.PubMed/NCBI
|
|
2
|
Rowland JM: Hepatoblastoma: Assessment of
criteria for histologic classification. Med Pediatr Oncol.
39:478–483. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Malogolowkin MH, Katzenstein HM, Krailo M
and Meyers RL: Treatment of hepatoblastoma: The North American
cooperative group experience. Front Biosci (Elite Ed). 4:1717–1723.
2012. View Article : Google Scholar
|
|
4
|
Warmann SW and Fuchs J: Drug resistance in
hepatoblastoma. Curr Pharm Biotechnol. 8:93–97. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cao R, Wang L, Wang H, Xia L,
Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y: Role of
histone H3 lysine 27 methylation in Polycomb-group silencing.
Science. 298:1039–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xiao Y: Enhancer of zeste homolog 2: A
potential target for tumor therapy. Int J Biochem Cell Biol.
43:474–477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen Y, Lin MC, Yao H, Wang H, Zhang AQ,
Yu J, Hui CK, Lau GK, He ML, Sung J and Kung HF:
Lentivirus-mediated RNA interference targeting enhancer of zeste
homolog 2 inhibits hepatocellular carcinoma growth through
down-regulation of stathmin. Hepatology. 46:200–208. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y,
Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, et al: EZH2 protein: A
promising immunomarker for the detection of hepatocellular
carcinomas in liver needle biopsies. Gut. 60:967–976. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hajósi-Kalcakosz S, Dezső K, Bugyik E,
Bödör C, Paku S, Pávai Z, Halász J, Schlachter K, Schaff Z and Nagy
P: Enhancer of zeste homologue 2 (EZH2) is a reliable
immunohistochemical marker to differentiate malignant and benign
hepatic tumors. Diagn Pathol. 7:862012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yonemitsu Y, Imazeki F, Chiba T, Fukai K,
Nagai Y, Miyagi S, Arai M, Aoki R, Miyazaki M, Nakatani Y, et al:
Distinct expression of polycomb group proteins EZH2 and BMI1 in
hepatocellular carcinoma. Hum Pathol. 40:1304–1311. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ougolkov AV, Bilim VN and Billadeau DD:
Regulation of pancreatic tumor cell proliferation and
chemoresistance by the histone methyltransferase enhancer of zeste
homologue 2. Clin Cancer Res. 14:6790–6796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kotake Y, Cao R, Viatour P, Sage J, Zhang
Y and Xiong Y: pRB family proteins are required for H3K27
trimethylation and Polycomb repression complexes binding to and
silencing p16INK4alpha tumor suppressor gene. Genes Dev. 21:49–54.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fujii S, Ito K, Ito Y and Ochiai A:
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by
increasing histone H3 methylation. J Biol Chem. 283:17324–17332.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakagawa S, Okabe H, Sakamoto Y, Hayashi
H, Hashimoto D, Yokoyama N, Sakamoto K, Kuroki H, Mima K, Nitta H,
et al: Enhancer of zeste homolog 2 (EZH2) promotes progression of
cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Ann Surg Oncol. 20(Suppl 3): S667–S675. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakurai T, Bilim VN, Ugolkov AV, Yuuki K,
Tsukigi M, Motoyama T and Tomita Y: The enhancer of zeste homolog 2
(EZH2), a potential therapeutic target, is regulated by miR-101 in
renal cancer cells. Biochem Biophys Res Commun. 422:607–614. 2012.
View Article : Google Scholar : PubMed/NCBI
|
